Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Gynecologic Oncology
•
Palliation
•
Medical Oncology
•
Supportive Care
How would you manage a patient with FIGO stage IIIB endometrial carcinoma who developed significant back pain with Carboplatin/Paclitaxel cycle 1, which worsened during cycle 2?
Related Questions
What normal tissue dose constraints do you use when delivering up to 3 cycles of the palliative quad shot regimen for gynecologic pelvic malignancies?
What do you view as the future role for the combination of durvalumab + olaparib + chemotherapy in the management of patients with advanced/recurrent endometrial cancer following the DUO-E trial results?
How would you manage concurrent immunotherapy-related colitis and C. difficile infection?
How would you palliate a large, symptomatic vaginal melanoma recurrence with limited small pelvic lymph node metastases?
Would you add dostarlimab to adjuvant carboplatin/paclitaxel in a patient with completely resected IIIA uterine carcinosarcoma (MSI-H)?
In a patient with oligometastatic, recurrent Grade 2, ER+, MSI-high endometrioid adenocarcinoma who has a single, resectable metastasis to bone, what systemic therapy would you recommend and how would you time it in relation to possible surgery?
In SIADH due to malignancy, do you prefer to use free water restriction or salt tablets?
Would you add olaparib to maintenance immunotherapy for a patient with recurrent MMR-proficient, HER2-negative serous endometrial carcinoma?
Can defibrotide be given safely for VOD in patients with refractory thrombocytopenia to platelet transfusions?
What are your top takeaways from SGO 2024?
